PHARMA TECH
assisTek Inc | June 21, 2022
assisTek, based in Doylestown, PA, has announced its latest partnership with Philadelphia based Strados Labs. Strados Labs is known for their creation of cutting-edge smart technology medical devices for respiratory illnesses.
assisTek, has been a longtime leader in the eSource industry across various therapeutic areas, over 900+ Global clinical Trials and offers an array of services for the electronic collection of clinical data. Their technology offerings include eCOA, ePRO, eConsent, BYOD modules and an extensive reputation for their custom solutions to support clinical trial teams worldwide. "We are very excited to announce this partnership and are looking forward to working together with Strados to provide another way for clinicians and patients to gather novel information during their trials. By making the integration seamless into our current eDiary offerings, this paired technology will allow for better patient engagement and more efficient information gathering, with the ultimate goal of improved data for cures and treatment of these conditions," explains Richard Gastineau, CEO of assisTek.
Strados Labs is a medical technology company developing smart sensor platforms that utilize machine learning and proprietary algorithms to detect and predict compounding conditions associated with serious, chronic respiratory diseases to improve the lives of patients globally. "We are grateful and proud to solidify our partnership with assisTek. They have been a leader in integrating technology and data collection in clinical trials for over 20 years," said Strados Labs Director of Business Development, Shane Krauss. "We look forward to working with their experienced and knowledgeable team in clinical trials by helping them scale their digital therapeutics using our clinically validated measures for wheeze, cough, and other adventitious breath sounds, or CABS—which is something no other cleared device can measure." The Company developed a first-of-its-kind smart sensor platform for respiratory health, RESP®. Strados recently received FDA Class II 510(k) clearance for home use of its first product, RESP®, its second FDA clearance in less than 18 months. RESP® was also granted a CE Mark late last year. The Company is developing a robust pipeline algorithm to support and address other chronic diseases, as well as chronic disease management pathways. Strados will continue to target asthma, COPD and infectious respiratory diseases (COVID, RSV, and more)—with plans to add heart failure and pediatrics later this year. The Company is based in Philadelphia and is a privately held company.
Read More
PHARMACY MARKET
MEDISCA | June 18, 2021
MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee.
MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company with 32 years of experience. The company's top priority is to automate processes throughout its sales, service, and marketing divisions and replace at least five disparate systems.
"We picked Creatio because of its unified low-code/no-code platform for process management and CRM, which will help us with our business and marketing demands," said Ekaterina Dobrokhotova, Director of Global Marketing. "We can manage the automation of our business processes with Creatio's low-code/no-code tools, giving us more control and flexibility over our operations. It also enables us to put more resources to more complicated, strategic tasks."
Creatio aims to assist companies in accelerating by providing solutions to quickly and easily automate business ideas. Creatio provides a modular approach to app development and process automation to help speed up processes even more. The out-of-the-box capacity of Creatio eliminates the need to build core modules for apps from scratch. Instead, its pre-configured modules provide similar basic functionalities required for several apps and can be useful to achieve new solutions more quickly.
Solutions Metrix is in charge of the system's implementation.
"In the increasingly competitive and rapidly evolving Pharmaceutical compounding market, we are excited to partner with MEDISCA to help them accelerate their growth and achieve strategic business objectives through the power of Creatio's industry-leading low-code/no-code platform," said Thomas James Stewart, Executive Vice-President & Managing Partner.
About Solutions Metrix
Since 2001, Solutions Metrix has been implementing globally known CRM platforms such as Creatio for the North American market across various industries and businesses of all sizes.
CRM consulting services from Solution Metrix focus on accelerating growth and accomplishing strategic business objectives for its partners/clients. Their team of seasoned Business & CRM Consultants will guarantee that every implementation is best practices focused and adapted to your company's specific business processes and needs, using a unique consultative approach & methodology that is ROI & user-adoption driven to assure success.
About MEDISCA
MEDISCA is the global leader in turnkey solutions for the pharmaceutical compounding industry and associated health care professionals. MEDISCA is committed to being a one-stop-shop for prescribers, pharmacists, and pharmacy technicians involved in personalized medicine by providing high-quality products, cutting-edge technology, industry-leading compounded support, and education through its partnership with LP3 Network. Founded in 1989, the company now has offices in Canada, the United States, and Australia, allowing it to serve the international market better.
Read More
PHARMACY MARKET
Yangtze River Pharmaceutical, TraceLink | May 06, 2021
TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, including the United States and Europe.
"As we approach our 50th anniversary this year, we are preparing to deliver our innovations to global markets beyond China," said Mr. Luo Bai Gui GM's Executive Assistant, International Projects from YRPG. "Given the broad scope of our portfolio and diverse business model, TraceLink' s integrated network, global compliance solutions and low total cost of ownership are crucial for us to achieve commercial success in multiple markets."
"Global commercialization has become a top priority during this special milestone year for YRPG and serialization compliance is a necessary step in their preparation for global expansion," said Shabbir Dahod, President and CEO, TraceLink. "As one of the top pharmaceutical enterprises in China, YRPG is highly esteemed for its relentless innovation and TraceLink is proud to be their serialization partner of record as they embark on their journey of continued global growth."
With more than 16,000 employees and over 20 subsidiaries located across China, YRPG has established R&D and production bases for innovative chemical medicines, patent traditional Chinese Medicine (TCMs) and biological medicines. Yangtze River Pharmaceutical Group's products include Chinese, Western medicines and APIs, covering ten fields, nearly 20 dosage forms and over 300 types of medicines and strengths. Nearly 100 innovative drugs for major diseases are currently under research & development.
About Yangtze River Pharmaceutical Group
With a total manufacturing footprint of more than 3 million square meters, Yangtze River Pharmaceutical Group employs 16,000 and owns 11 manufacturing subsidiaries located in Beijing, Shanghai, Nanjing, Guangzhou, etc. The company fields established R&D and production bases for innovative chemical medicines, patent traditional Chinese Medicine (TCM) and biological medicines. Currently, Yangtze River Pharmaceutical Group exports part of its portfolio assortment to 30 countries including Europe, Asia and Africa.
About TraceLink
TraceLink is the only business network creation platform for building integrated business ecosystems with multienterprise applications. Business networks are the foundation of an Industry 4.0 digitalization strategy that delivers customer-centric agility and resiliency of the end-to-end supply network leveraging the collective intelligence of an industry. TraceLink's Opus Digital Network Platform enables speed of open innovation and implementation with a partner ecosystem for no-code and low-code development of solutions and applications.
Read More